Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma
The purpose of this study is to access the safety and efficacy of neoadjuvant Immunotherapy (Sintilimab, PD-1 inhibitor) combined with chemotherapy (Tegafur+Oxaliplatin) for locally advanced esophagogastric junction adenocarcinoma.
Esophagogastric Junction Adenocarcinoma
DRUG: Sintilimab
Pathologic Complete Response, No malignant tumor cells were detected in the removed specimens including primary tumor and lymph nodes, From date of enrollment until one month after resection
Overall survival, The time from randomization to death from any cause., 2-5 years|Disease-Free-Survival, The time between the beginning of treatment and the observation of disease progression or death from any cause., 2-5 years|R0 resection rate, The percentage of patients who undergo complete resection, From date of enrollment until one month after resection
The purpose of this study is to access the safety and efficacy of neoadjuvant Immunotherapy (Sintilimab, PD-1 inhibitor) combined with chemotherapy (Tegafur+Oxaliplatin) for locally advanced esophagogastric junction adenocarcinoma.